BETA SAÚDE
10,11-Seco-LSD
Texto da Wikipédia (en), licença CC BY-SA. O BETARUBI mostra o verbete inteiro nesta página — a leitura não continua fora do site.
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | "[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide |
| Drug class | Partial ergoline |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
10,11-Seco-LSD is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).[1] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.[1] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.[1] Its pharmacology was not described.[1]

See also
- Partial lysergamide
- Seco-LSD
- Secoergoline
- NDTDI (8,10-seco-LSD)
- DEIMDHPCA (3,5-seco-LSD)
References
- 1 2 3 4 WO 2021076572, Olson DE, Dunlap LM, Wagner F, Chytil M, Powell NE, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California
This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information. |
